Phase 1 Study of INBRX-105 in Patients With Solid Tumors, Hodgkin or Non-Hodgkin Lymphoma
Conditions: Metastatic Solid Tumors; Hodgkin Lymphoma; Non Hodgkin Lymphoma (NHL); Non-small Cell Lung Cancer (NSCLC); Melanoma; Head and Neck Squamous Cell Carcinoma (HNSCC); Gastric Adenocarcinoma; Renal Cell Carcinoma (RCC); Urothelial Carcinoma; Esophageal Adenocarcinoma Intervention: Drug: INBRX-105 Sponsor: Inhibrx, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Cancer & Oncology | Carcinoma | Esophagus Cancer | Gastroenterology | HNSCC | Lymphoma | Melanoma | Non-Hodgkin's Lymphoma | Non-Small Cell Lung Cancer | Research | Skin Cancer | Study